IBIO

iBio, Inc. develops next-generation therapies for cardiometabolic diseases, focusing on creating safe and effective treatment options. The company utilizes an AI-integrated platform to discover antibodies for challenging, validated targets, aiming to expedite the clinical development of therapeutics. iBio's programs address specific unmet medical needs, such as preserving muscle during weight loss and preventing weight regain, and it operates primarily in the biopharmaceutical sector.